Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tau-targeting therapies for Alzheimer disease: current status and future directions
Erin E. Congdon, Changyi Ji, Amber M. Tetlow, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 12, pp. 715-736
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
Itsuki Terao, Wakako Kodama
Ageing Research Reviews (2024) Vol. 94, pp. 102203-102203
Closed Access | Times Cited: 47
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 19
Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
James Naude, Meng Wang, Rebeca Leon, et al.
Neurobiology of Aging (2024) Vol. 138, pp. 19-27
Open Access | Times Cited: 16
Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review
J Yang, Weijia Zhi, Lifeng Wang
Molecules (2024) Vol. 29, Iss. 12, pp. 2812-2812
Open Access | Times Cited: 13
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges
Huiting Zheng, Huimin Sun, Qixu Cai, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4969-4969
Open Access | Times Cited: 12
Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies
Einar M. Sigurdsson
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S129-S140
Closed Access | Times Cited: 10
Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer’s Disease
Mona Abdelhamid, Scott Counts, Chunyu Zhou, et al.
Nutrients (2025) Vol. 17, Iss. 3, pp. 558-558
Open Access | Times Cited: 1
Overexpression of TGFBR3 Aggravates Cognitive Impairment and Neuroinflammation by Promoting Microglia M1 Polarization in the APP/PS1 Mouse Model of Alzheimer's Disease
Hui Song, Mingyan Xia, Peng Zhao, et al.
Molecular Neurobiology (2025)
Closed Access | Times Cited: 1
The roles of intrinsically disordered proteins in neurodegeneration
Kagistia Hana Utami, Satoru Morimoto, Yasue Mitsukura, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2025), pp. 130772-130772
Open Access | Times Cited: 1
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities
Lisha Wang, Sooram Banesh, Rajnish Kumar, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access | Times Cited: 1
Intraneuronal Aβ accumulation causes tau hyperphosphorylation via endolysosomal leakage
Yang Gao, Lisha Wang, Tosca Doeswijk, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access | Times Cited: 1
A Nanozyme-Boosted MOF-CRISPR Platform for Treatment of Alzheimer’s Disease
Jie Yang, Geng Qin, Zhenqi Liu, et al.
Nano Letters (2024) Vol. 24, Iss. 32, pp. 9906-9915
Closed Access | Times Cited: 7
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Ali Aljassabi, Tarek Zieneldien, Janice Kim, et al.
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 3, pp. 755-772
Closed Access | Times Cited: 6
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
CSF and plasma biomarkers in cerebral amyloid angiopathy: A single-center study and a systematic review/meta-analysis
Aikaterini Theodorou, Ioanna Tsantzali, Maria‐Ioanna Stefanou, et al.
European Stroke Journal (2024)
Closed Access | Times Cited: 6
The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer’s Disease: Role for Natural Antioxidants and Immunotherapeutics
Ali Jawad, Kyonghwan Choe, Jun Sung Park, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 862-862
Open Access | Times Cited: 6
Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds
Huahua Shi, Yan Zhao
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 831-831
Open Access | Times Cited: 5
Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer’s Disease
Sunghwa Kim, Irfan Ullah, Jagadish Beloor, et al.
Biomaterials Research (2024) Vol. 28
Open Access | Times Cited: 5
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Judite R.M. Coimbra, Rosa Resende, José B.A. Custódio, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S53-S78
Closed Access | Times Cited: 5
Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer’s Disease: Recent Advances and Perspectives
Naoyuki Suzuki, T. Hatta, Mana Ito, et al.
Chemical and Pharmaceutical Bulletin (2024) Vol. 72, Iss. 7, pp. 602-609
Open Access | Times Cited: 5
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies
Xingyu Zhang, Jiangyu Wang, Zhentao Zhang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer
Yizhao Chen, Qianling Xin, Mengjuan Zhu, et al.
Journal of Advanced Research (2025)
Open Access
Uncovering the epigenetic regulatory clues of PRRT1 in Alzheimer’s disease: a strategy integrating multi-omics analysis with explainable machine learning
Fang Wang, Ying Liang, Qinwen Wang
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access
Essential tremor with tau pathology features seeds indistinguishable in conformation from Alzheimer’s disease and primary age-related tauopathy
Nil Saez-Calveras, Jaime Vaquer-Alicea, Charles L. White, et al.
Acta Neuropathologica (2025) Vol. 149, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top